- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03388723
Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus (InDiaGDM)
The Role of Epigenetics in the Vicious Cycle of Diabetes and Pregnancy (VICYDIP)
Study Overview
Status
Conditions
Detailed Description
The DOHaD paradigm proposes that early life nutrition and growth influence health and disease risk across the life-course. Intrauterine period is the most crucial period in these events, and contributes to fetal programming. Fetal undernutrition as well as over-nutrition (maternal obesity and diabetes) increase risk of diabetes in the offspring. Current thinking is that fetal programming is an 'epigenetic' phenomenon and the most prominent mechanism may be methylation of DNA and histones that regulate gene expression in key pathways. The investigators have previously highlighted a role for maternal micronutrients in fetal programming of adiposity, insulin resistance, and prediabetes (nutrient mediated teratogenesis). Now, the investigators propose to study the impact of maternal hyperglycemia during pregnancy on the future risk of diabesity in the offspring (fuel mediated teratogenesis). This programme, first of its kind in India, will undertake 'OMICs' measurements (DNA methylation and targeted metabolomics) on cord blood samples of children born to women with gestation diabetes mellitus (GDM), in studies in Pune, Western India (Arm-1) and Punjab, North India (Arm-2). Markers identified in the discovery phase will be investigated for validity and stability in blood, cord blood and placenta samples from children born to GDM mothers in the older cohorts in Pune and Punjab. Danish investigators will perform complimentary measurements in the Danish National Birth Cohort which will allow comparison of epigenetic markers in these two populations with widely different prevalence of GDM, and ethnic and nutritional factors. Special attention will be given to role of nutritional and lifestyle factors of mothers which influence the programming of fetal epigenome during pregnancy. The biobank of maternal, cord and offspring samples will be available in future to test newer hypotheses. This study will benefit from technology transfer across two countries. The findings will add substantially to the evidence base of intergenerational transmission of diabetes in a diabetic pregnancy, and will inform policy-makers to help curb the escalating epidemic of diabetes in India.
Hypotheses
- The molecular mechanisms underlying the associations between gestational diabetes in the mother and diabesity in the offspring may involve permanent changes of DNA methylations in various tissues including blood cells obtained at birth and/or during childhood defining different trajectories.
- Epigenetic fingerprints linking GDM with risk of T2D among the offspring may or may not be influenced by tissue of origin, diet, life-style and ethnicity of population.
- Epigenetic changes in blood cells obtained at birth and/or during childhood associated with GDM in pregnancy may be used as bio-markers to predict later development of T2D in the offspring
- The risk of developing diabetes among offspring of GDM women may be influenced by maternal factors operating during pregnancy including degree of hyperglycemia, obesity, dietary factors including composition of macro- and micronutrients, and/or by the level of physical activity of the mother.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Pune, Maharashtra, India, 411011
- KEM hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Arm 1 and Arm 2: GDM women (diagnosed on OGTT) and women with normal glucose tolerance on OGTT and their offspring.
Arm 3: Offspring of diabetic mothers and non diabetic mothers
Description
Inclusion Criteria:
Arm 1 and 2:
- GDM or NGT on 75g OGTT (IADPSG Criteria).
- Willing to participate and sign consent
- Planned delivery at study site
- Age > 18 years
- Singleton pregnancy.
Arm 3:
1. Offspring of diabetic mothers and non diabetic mothers ( >2 years of age).
Exclusion Criteria:
Arm 1 and 2:
- Severe medical/ surgical illness detrimental to pregnancy or delivery (Severe liver, renal, cardiovascular, pulmonary, hematologic, endocrine disorder or long term steroid use for any reason)
- K/C/O Diabetes (Type 1 or Type 2 or any other type)
- Severe anemia (Hemoglobin< 9 gm% in first trimester and < 8 gm% in second or third trimester)
- IVF pregnancy.
Arm 3: None.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Arm 1: Discovery phase
Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:
|
Arm 2: Validation phase
Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
|
Arm 3: Stability phase
Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epigenetic signatures in the cord blood of the offspring of GDM mothers.
Time Frame: Upto 3 years from the start of the study
|
The Illumina Infinium Human Methylation 450K array will be used for DNA methylation study.
It generates a quantitative measurement of DNA methylation for >480,000 CpG sites spanning all annotated genes and other functional motifs.
Markers influencing risk of diabetes and obesity will be of special interest.
Approximately 150 GDM and 150 normal glucose tolerant pregnancies will contribute the samples.
|
Upto 3 years from the start of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association of the genotype with differentially methylated DNA regions.
Time Frame: Upto 3.5 years from the start of the study
|
The Human OmniExpress Exome BeadChip will be used for generating genome wide data.
It provides a backbone of >700,000 genome-wide markers (SNPs >5% minor allele frequencies) and 240,000 coding SNPs of all frequencies.
This will allow to identify the variants that act as meQTLS.
|
Upto 3.5 years from the start of the study
|
Validation of the epigenetic signatures generated in Primary Outcome 1.
Time Frame: Upto 3.5 years from the start of the study
|
Quantitative profile of DNA methylation at specific CpG sites will be done using Bisulfite Pyrosequencing [Sequenom EpiTYPER], in cord blood samples obtained in Pune and in Ludhiana.
|
Upto 3.5 years from the start of the study
|
Stability of epigenetic signatures discovered in the cord blood in offspring GDM mothers from childhood through adolescence.
Time Frame: Upto 4 years from the start of the study
|
The cord blood differential epigenetic signatures will be investigated in the blood sample of the offspring of GDM mothers during childhood and adolescence.
These children were born to GDM patients attending the diabetes clinic at KEM hospital, Pune over last 2 decades.
|
Upto 4 years from the start of the study
|
Association between epigenetic signatures and offspring phenotype at birth , and in childhood and adolescence.
Time Frame: Upto 4 years from the start of the study
|
Following phenotype measures will be tested :
|
Upto 4 years from the start of the study
|
Qualitative and quantitative comparison of epigenetic signatures in the offspring of GDM mothers [Indian and Danish cohort].
Time Frame: Upto 4.5 years from the start of the study
|
Epigenetic signatures from Indian and Denmark cohorts will be compared, taking into account differences in genetic background, nutrition and lifestyle. Comparison will focus on the direction and strength of associations, and the metabolic pathways implicated in the above analysis. |
Upto 4.5 years from the start of the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chittaranjan Chittaranjan, MD FRCP, Director, Diabetes Unit, KEM Hospital Research Centre
Publications and helpful links
General Publications
- Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J Pediatr Endocrinol Metab. 2001 Sep-Oct;14(8):1085-91. doi: 10.1515/jpem-2001-0803.
- Petitt DJ, Bennett PH, Knowler WC, Baird HR, Aleck KA. Gestational diabetes mellitus and impaired glucose tolerance during pregnancy. Long-term effects on obesity and glucose tolerance in the offspring. Diabetes. 1985 Jun;34 Suppl 2:119-22. doi: 10.2337/diab.34.2.s119.
- Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008 Jul 3;359(1):61-73. doi: 10.1056/NEJMra0708473. No abstract available.
- Wu L, Cui L, Tam WH, Ma RC, Wang CC. Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. Sci Rep. 2016 Jul 29;6:30539. doi: 10.1038/srep30539.
- Ma RC, Tutino GE, Lillycrop KA, Hanson MA, Tam WH. Maternal diabetes, gestational diabetes and the role of epigenetics in their long term effects on offspring. Prog Biophys Mol Biol. 2015 Jul;118(1-2):55-68. doi: 10.1016/j.pbiomolbio.2015.02.010. Epub 2015 Mar 16.
- Yajnik CS. Fetal programming of diabetes: still so much to learn! Diabetes Care. 2010 May;33(5):1146-8. doi: 10.2337/dc10-0407. No abstract available.
- Kale SD, Yajnik CS, Kulkarni SR, Meenakumari K, Joglekar AA, Khorsand N, Ladkat RS, Ramdas LV, Lubree HG. High risk of diabetes and metabolic syndrome in Indian women with gestational diabetes mellitus. Diabet Med. 2004 Nov;21(11):1257-8. doi: 10.1111/j.1464-5491.2004.01337.x. No abstract available.
- Kale SD, Kulkarni SR, Lubree HG, Meenakumari K, Deshpande VU, Rege SS, Deshpande J, Coyaji KJ, Yajnik CS. Characteristics of gestational diabetic mothers and their babies in an Indian diabetes clinic. J Assoc Physicians India. 2005 Oct;53:857-63.
- Yajnik CS. Transmission of obesity-adiposity and related disorders from the mother to the baby. Ann Nutr Metab. 2014;64 Suppl 1:8-17. doi: 10.1159/000362608. Epub 2014 Jul 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEMHRC ID No. 1404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany